SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-008436
Filing Date
2021-02-25
Accepted
2021-02-25 07:42:36
Documents
14
Period of Report
2021-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-8k_20210225.htm   iXBRL 8-K 42136
2 EX-99.1 ntla-ex991_6.htm EX-99.1 178638
3 GRAPHIC guqnm4tvoboa000001.jpg GRAPHIC 44771
  Complete submission text file 0001564590-21-008436.txt   427852

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ntla-20210225.xsd EX-101.SCH 5768
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20210225_lab.xml EX-101.LAB 19470
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20210225_pre.xml EX-101.PRE 11624
7 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20210225_htm.xml XML 3550
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 21676445
SIC: 2835 In Vitro & In Vivo Diagnostic Substances